The purpose of this study is to determine if Quinidine therapy (not guided by the results of electrophysiologic studies) will reduce the long-term risk of arrhythmic events in asymptomatic Brugada Syndrome.
Prevention, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study.
A Prospective Trial Of Empiric Quinidine Therapy For Asymptomatic Brugada Syndrome.
Drug: no therapy
Patients with type I Brugada electrocardiogram
(either spontaneous or following a drug challenge
with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive Quinidine therapy at the discretion of the attending physician.
Quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
|No therapy: Active Comparator
Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
|Drug: no therapy
- Following the approval of the new manufacturer by the French Health Authority (the Agence Nationale de Sécurité du Médicament, the ANSM), Serecor® 300mg prolonged-release capsules are again available.
- Initial prescriptions of Serecor® 300mg prolonged-release capsules are restricted to cardiologists;
- Repeat prescriptions are not restricted to cardiologists.
- Also, Supplies of QUINIDINE SULFATE 200 mg can be purchased directly from Rekah Pharmaceuticals in Israel by contacting Mr. Yaacov Elgrabli at email@example.com Quinidine should only be taken under medical supervision.
The trial is registered at: